Clinical Dosing Data and Pen-Based Interpretation Phase 2 Obesity Trial (48 Weeks) The pivotal Phase 2 trial demonstrated: Up to ~24% mean weight reduction Strong dose-response relationship Higher doses associated with greater metabolic improvement Reference: Clinical trial registry: Phase 2 Type 2 Diabetes Study Parallel metabolic trials demonstrated: Significant HbA1c reductions Improved fasting glucose Improved post-prandial glucose control Reduction in insulin resistance markers Reference: Coskun T et al., Cell Metabolism , 2022 Dose Escalation Strategy Across studies, retatrutide was not initiated at target doses
Safety and tolerability of oral semaglutide were consistent with subcutaneous liraglutide 1.8 mg in the PIONEER 4 study [9]
Let this be your reset not just for weight, but for whole-body regulation, vitality, and freedom
The most common side effects with GLP-1 peptides are nausea, constipation, and bloating, especially in the first few weeks
If it means more hair for years, I am willing to swallow the pills, to use the serum, to swear off ponytails
Vaughn AR, Branum A, Sivamani RK